| I-05 Miro Eigenmann PBPK modeling approach to study the impact of lymph flow on the biodistribution of therapeutic antibodies Wednesday 10:20-11:40 |
| I-15 Saskia Fuhrmann Generic PBPK model to predict preclinical and clinical PK of antibodies Wednesday 10:20-11:40 |
| I-25 Ignacio Gonzalez-Garcia Assessment of in vitro dissolution specifications based on an IVIVC and in vivo bioequivalence criteria Wednesday 10:20-11:40 |
| I-36 Nina Hanke Physiologically-based Pharmacokinetic Modeling of Rifampin Drug-Drug Interactions with Midazolam and Digoxin Wednesday 10:20-11:40 |
| I-45 Xiao Hu Population pharmacokinetic analysis of fampridine in Japanese patients with multiple sclerosis in a Phase 3 study Wednesday 10:20-11:40 |
| I-53 Masoud Jamei Time variation in the fractional contribution of an enzyme to elimination of a victim drug can explain differences in DDI susceptibility following single and multiple dosing Wednesday 10:20-11:40 |
| I-56 Jong Bong Lee Predicted versus experimental permeability data for incorporation into GastroPlus for modelling and simulations Wednesday 10:20-11:40 |
| II-15 Kathryn Ball Prediction of food effect in the Chinese population using a PBPK model developed in a Caucasian population Wednesday 15:10-16:30 |
| II-31 Hannah Britz Physiologically-Based Pharmacokinetic (PBPK) Modeling of the Dronedarone Drug-Drug Interaction with Digoxin Wednesday 15:10-16:30 |
| II-49 Yumi Cleary Physiologically based pharmacokinetic (PBPK) and population PK (PPK) modeling for basimglurant - assessment of predicted variability by the PBPK model and its utility Wednesday 15:10-16:30 |
| II-57 André Dallmann Validation of a Population Physiologically-Based Pharmacokinetic Model for Pregnant Women Wednesday 15:10-16:30 |
| II-60 Miné De Kock Pharmacokinetics of Sulfadoxine and Pyrimethamine for intermittent preventive treatment of malaria during Pregnancy and after delivery. Wednesday 15:10-16:30 |
| II-62 Mailys De Sousa Mendes A physiologically based pharmacokinetic model for a drug metabolized by several CYP450 during pregnancy Wednesday 15:10-16:30 |
| III-08 Gaohua Lu A Novel Mechanistic Approach to Predict the Steady State Volume of Distribution (Vss) using the Fick-Nernst-Planck Equation Thursday 10:05-11:30 |
| III-29 Morris Muliaditan Prediction of the exposure of anti-tuberculosis drugs in lung tissue: implications for dose selection Thursday 10:05-11:30 |
| III-37 Andrés Olivares-Morales Combining population with physiologically-based pharmacokinetic (PBPK) models for oral drug absorption: Predicting the segmental bioavailability differences of R-oxybutynin and its main metabolite using a middle out approach. Thursday 10:05-11:30 |
| III-63 Christian Radke Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis Thursday 10:05-11:30 |
| IV-26 Donato Teutonico Whole-body PBPK/PD modelling of ciprofloxacin and its anti-bacterial activity Thursday 14:40-16:00 |
| IV-30 Huybrecht T'jollyn Pharmacokinetics of galantamine in plasma and brain for different intranasal formulations: an experimental in vivo study Thursday 14:40-16:00 |
| IV-38 Ken-ichi Umehara Assessment of DDI potential of ruxolitinib (INC424), a dual substrate of CYP3A4 and CYP2C9, using a verified PBPK model to support submissions to Health Authorities Thursday 14:40-16:00 |
| IV-53 Ulrika Wählby Hamrén Pharmacokinetics of the inhaled selective glucocorticoid receptor modulator AZD5423 following inhalation using different devices Thursday 14:40-16:00 |
